Chronic Malignancies Working Party

CLL & PCD & PH&G

Activities of the working party and subcommittees

Chair: Ibrahim Yakoub-Agha

Secretary: Patrick Hayden

Email address: cmwpebmt@lumc.nl

Subcommittee Chronic Lymphocytic Leukemia (CLL)

Chair: Olivier Tournilhac, Vice-chair: Michel van Gelder



Ongoing studies

Allogeneic transplantation for CLL – *Olivier Tournilhac and Michel van Gelder*

#1: 10-year (2009-2019) EBMT landscape of AlloSCT for CLL (10-year ELAC).

#2: AlloSCT after Multiple PI (AMPI).

#3: AlloSCT after stopping Ibrutinib for intolerance or relapse (ASTIIR).

#4: Venetoclax before and after alloSCT for CLL (VenAC).

Autologous and allogeneic HSCT for Richter's Syndrome (2008-2018) – *Romain Guièze*

The prognosis of Richter's syndrome (RS) is very poor as a result of and resistance to salvage treatment and overall survival following Richter transformation is usually less than 1 year. In this context, both autologous and allogeneic transplantation are strategies that have been proposed and even recommended in consolidation when remission can be achieved. We propose to analysis transplantation in Richter syndrome, with the hope of determining prognostic factors predictive of evolution. We believe that this study is important given the recent development of BCRi and BCL2i, and the emergence of Richter syndromes in this context.

T-cell prolymphocytic leukemia: autologous transplantation – *Joanna Drozd-Sokołowska*

T-cell prolymphocytic leukemia is a rare entity with poor prognosis. While alemtuzumab administered intravenously is considered a golden standard first line, yielding response in >90% patients, there is a strong need for both remission consolidation and effective treatment of relapse. There are many studies reporting on allogeneic HSCT for these indications. Although ASCT might not provide a cure to T-PLL patients, it might be a viable option for older, less fit patients. The aim of this study is to evaluate the outcomes of T-PLL patients receiving ASCT.

Hairy Cell Leukemia: allogeneic transplantation - *Dai Chihara*

Hairy cell leukemia (HCL) is an indolent B-cell neoplasm comprising 2% of leukemias. There remain continuous unmet needs for new treatment strategies particularly for relapsed/refractory HCL. This retrospective study aims to describe the clinical outcomes and evaluate the benefit of allogeneic HSCT in patients with HCL.

Most recent publications

Outcomes and toxicity of allogeneic hematopoietic cell transplantation in chronic myeloid leukemia patients previously treated with second-generation tyrosine kinase inhibitors: a prospective non-interventional study from the Chronic Malignancy Working Party of the EBMT – *S. Masouridi-Levrat et al. Bone Marrow Transplant. 2022 Jan;57(1):23-30. doi: 10.1038*

Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced-intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT – *A. Shimoni et al. Br J Haematol. 2021 Nov;195(3):417-428. doi: 10.1111/bjh.17817*

Impact of donor-derived CD34 + infused cell dose on outcomes of patients undergoing allo-HCT following reduced intensity regimen for myelofibrosis: a study from the Chronic Malignancies Working Party of the EBMT – *T. Czerw et al. doi: Bone Marrow Transplant. 2022 Feb;57(2):261-270. doi: 10.1038/s41409-021-01540-2*

Autologous hematopoietic cell transplantation for relapsed multiple myeloma performed with cells procured after previous transplantation - study on behalf of CMWP of the EBMT – *J. Drozd-Sokolowska et al. Bone Marrow Transplant. 2022 Feb 15. doi: 10.1038/s41409-022-01592-y.*

Trends in Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: Changing demographics and outcomes in EBMT centres from 1995 to 2019 – *D. Swan et al. Br J Haematol. 2022 Feb 15. doi: 10.1111/bjh.18025*

Trends in allogeneic haematopoietic cell transplantation for myelofibrosis in Europe between 1995 and 2018: a CMWP of EBMT retrospective analysis – *D. McLornan et al. doi: Bone Marrow Transplant. 2021 Sep;56(9):2160-2172. doi: 10.1038/s41409-021-01305-x*

Subcommittee Plasma Cell Disorders (PCD)

Chair: Stefan Schönland, Vice-chair: Meral Beksaç





Ongoing studies

Trends in Autologous Stem Cell Mobilisation Practices for Myeloma in EBMT centres between 2008 and 2019 – *Patrick Hayden*

Impact of Extramedullary Disease on Outcome after Autologous Transplant and Maintenance Treatment: a study from the CMWP of EBMT – *Nico Gagelmann*

Second line ASCT after KRD induction in Multiple Myeloma – *Salomon Manier*

Upcoming data requests

Daratumumab before allo in Multiple Myeloma: tolerability and efficacy – *Laure Vincent*

Daratumumab is a humanized monoclonal anti-CD38 antibody approved both for first line and rescue treatment of multiple myeloma. The aim of this retrospective study is to assess the impact of the use of daratumumab before allogeneic HSCT on graft versus myeloma effect and post-transplant toxicity.

Outcome of autologous stem cell transplantation in Light Chain Deposition Disease (LCDD) – *Laurent Garderet*

Light/heavy chain deposition disease is a rare disease involving a monoclonal light chain, most often kappa, secreted by abnormal bone marrow monoclonal plasmocytes. Its treatment is very similar to the treatment of myeloma, however the role of ASCT remains controversial in this setting, especially because these patients quite often have renal impairment, sometimes with the need of dialysis. Therefore, ASCT toxicity and morbidity in this setting is a challenge. The goal of this retrospective study is to analyze the outcome of ASCT in terms of toxicity and efficacy, both hematological and other organ responses.

Monday March 21st, 2022 – South Hall 1A+B / Virtual Hall 4

Oral session 1: Lymphoma, CLL and multiple myeloma

09:27 – 09:36 OS01-04 An early post-transplant relapse prediction score in Multiple Myeloma patients: a large cohort study from Chronic Malignancies Working Party – *Beksac et al.*

09:36 – 09:45 OS01-05 International differences in baseline characteristics and practice patterns in newly diagnosed Multiple Myeloma (MM) patients undergoing upfront autologous stem cell transplantation – *Garderet et al.*

Subcommittee Practice Harmonization and Guidelines (PH&G)

Chair: Patrick Hayden, Vice-chair: Laurent Garderet

Ongoing studies

Management of CMML patients – recommendation paper – *Onida et al.*

Please feel free to contact us if you would like to lead on the production of a new guideline. These projects lend themselves to virtual meetings and conference calls.

We particularly encourage haematologists-in-training as there is a depth of experience in the CMWP to support you in your chosen project.

In case of any questions, please email Patrick Hayden at secretaryebmtcmwp@stjames.ie